S W Hetts1, T Tsai2, D L Cooke2, M R Amans2, F Settecase2, P Moftakhar2, C F Dowd3, R T Higashida3, M T Lawton4, V V Halbach3. 1. From the Departments of Radiology and Biomedical Imaging (S.W.H., T.T., D.L.C., M.R.A., F.S., P.M., C.F.D., R.T.H., V.V.H.) steven.hetts@ucsf.edu. 2. From the Departments of Radiology and Biomedical Imaging (S.W.H., T.T., D.L.C., M.R.A., F.S., P.M., C.F.D., R.T.H., V.V.H.). 3. From the Departments of Radiology and Biomedical Imaging (S.W.H., T.T., D.L.C., M.R.A., F.S., P.M., C.F.D., R.T.H., V.V.H.) Neurological Surgery (C.F.D., R.T.H., M.T.L., V.V.H.) Neurology (C.F.D., R.T.H., V.V.H.) Anesthesia and Perioperative Care (C.F.D., R.T.H., V.V.H.), University of California, San Francisco, San Francisco, California. 4. Neurological Surgery (C.F.D., R.T.H., M.T.L., V.V.H.).
Abstract
BACKGROUND AND PURPOSE: A minority of intracranial dural arteriovenous fistulas progress with time. We sought to determine features that predict progression and define outcomes of patients with progressive dural arteriovenous fistulas. MATERIALS AND METHODS: We performed a retrospective imaging and clinical record review of patients with intracranial dural arteriovenous fistula evaluated at our hospital. RESULTS: Of 579 patients with intracranial dural arteriovenous fistulas, 545 had 1 fistula (mean age, 45 ± 23 years) and 34 (5.9%) had enlarging, de novo, multiple, or recurrent fistulas (mean age, 53 ± 20 years; P = .11). Among these 34 patients, 19 had progressive dural arteriovenous fistulas with de novo fistulas or fistula enlargement with time (mean age, 36 ± 25 years; progressive group) and 15 had multiple or recurrent but nonprogressive fistulas (mean age, 57 ± 13 years; P = .0059, nonprogressive group). Whereas all 6 children had fistula progression, only 13/28 adults (P = .020) progressed. Angioarchitectural correlates to chronically elevated intracranial venous pressures, including venous sinus dilation (41% versus 7%, P = .045) and pseudophlebitic cortical venous pattern (P = .048), were more common in patients with progressive disease than in those without progression. Patients with progressive disease received more treatments than those without progression (median, 5 versus 3; P = .0068), but as a group, they did not demonstrate worse clinical outcomes (median mRS, 1 and 1; P = .39). However, 3 young patients died from intracranial venous hypertension and intracranial hemorrhage related to progression of their fistulas despite extensive endovascular, surgical, and radiosurgical treatments. CONCLUSIONS: Few patients with dural arteriovenous fistulas follow an aggressive, progressive clinical course despite treatment. Younger age at initial presentation and angioarchitectural correlates to venous hypertension may help identify these patients prospectively.
BACKGROUND AND PURPOSE: A minority of intracranial dural arteriovenous fistulas progress with time. We sought to determine features that predict progression and define outcomes of patients with progressive dural arteriovenous fistulas. MATERIALS AND METHODS: We performed a retrospective imaging and clinical record review of patients with intracranial dural arteriovenous fistula evaluated at our hospital. RESULTS: Of 579 patients with intracranial dural arteriovenous fistulas, 545 had 1 fistula (mean age, 45 ± 23 years) and 34 (5.9%) had enlarging, de novo, multiple, or recurrent fistulas (mean age, 53 ± 20 years; P = .11). Among these 34 patients, 19 had progressive dural arteriovenous fistulas with de novo fistulas or fistula enlargement with time (mean age, 36 ± 25 years; progressive group) and 15 had multiple or recurrent but nonprogressive fistulas (mean age, 57 ± 13 years; P = .0059, nonprogressive group). Whereas all 6 children had fistula progression, only 13/28 adults (P = .020) progressed. Angioarchitectural correlates to chronically elevated intracranial venous pressures, including venous sinus dilation (41% versus 7%, P = .045) and pseudophlebitic cortical venous pattern (P = .048), were more common in patients with progressive disease than in those without progression. Patients with progressive disease received more treatments than those without progression (median, 5 versus 3; P = .0068), but as a group, they did not demonstrate worse clinical outcomes (median mRS, 1 and 1; P = .39). However, 3 young patients died from intracranial venous hypertension and intracranial hemorrhage related to progression of their fistulas despite extensive endovascular, surgical, and radiosurgical treatments. CONCLUSIONS: Few patients with dural arteriovenous fistulas follow an aggressive, progressive clinical course despite treatment. Younger age at initial presentation and angioarchitectural correlates to venous hypertension may help identify these patients prospectively.
Authors: R P Atkinson; I A Awad; H H Batjer; C F Dowd; A Furlan; S L Giannotta; C R Gomez; D Gress; G Hademenos; V Halbach; J C Hemphill; R T Higashida; L N Hopkins; M B Horowitz; S C Johnston; M W Lawton; M W McDermott; A M Malek; J P Mohr; A I Qureshi; H Riina; W S Smith; J Pile-Spellman; R F Spetzler; T A Tomsick; W L Young Journal: Stroke Date: 2001-06 Impact factor: 7.914
Authors: S L Barnwell; V V Halbach; C F Dowd; R T Higashida; G B Hieshima; C B Wilson Journal: AJNR Am J Neuroradiol Date: 1991 May-Jun Impact factor: 3.825
Authors: Stephan Dützmann; Jürgen Beck; Rüdiger Gerlach; Andrea Bink; Joachim Berkefeld; Richard du Mesnil de Rochement; Volker Seifert; Andreas Raabe Journal: Acta Neurochir (Wien) Date: 2011-03-20 Impact factor: 2.216
Authors: S W Hetts; K Keenan; H J Fullerton; W L Young; J D English; N Gupta; C F Dowd; R T Higashida; M T Lawton; V V Halbach Journal: AJNR Am J Neuroradiol Date: 2012-07-05 Impact factor: 3.825
Authors: Perry P Ng; Randall T Higashida; Sean Cullen; Reza Malek; Van V Halbach; Christopher F Dowd Journal: Neurosurg Focus Date: 2003-10-15 Impact factor: 4.047
Authors: Sara C LaHue; Helen Kim; Ludmila Pawlikowska; Jeffrey Nelson; Daniel L Cooke; Steven W Hetts; Vineeta Singh Journal: J Neurosurg Date: 2018-04-01 Impact factor: 5.115
Authors: S W Hetts; A Yen; D L Cooke; J Nelson; P Jolivalt; J Banaga; M R Amans; C F Dowd; R T Higashida; M T Lawton; H Kim; V V Halbach Journal: AJNR Am J Neuroradiol Date: 2017-09-28 Impact factor: 3.825